factual

Melflufen approved on weak trial, may have harmed patients

Melflufen, a 1960s drug with a small molecule added, was approved based on an uncontrolled myeloma study, then in a randomized trial against the weakest acceptable control arm showed no survival benefit with a hazard ratio trending toward harm—illustrating that taxpayer money paid for a drug that may have hurt patients relative to not having it at all.

factualpending

Speaker

Vinay Prasad

Evidence Quote

“the hazard ratio trends towards harm... the company was asked to withdraw the product from the U.S. market.”

Source

Vinay Prasad on Pharmaceuticals, the FDA, and the Death of Duty— EconTalk
Created: 6/13/2026, 3:32:57 AM

Your notes

Loading notes...